相关临床试验
12
7 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1853
进行中（未招募）
3
25.0%
已完成
2
16.7%
尚未招募
4
33.3%
招募中
3
25.0%
暂无批准数据
- The Molecular Imaging World Summit 2026 in Copenhagen highlighted long axial field-of-view (LAFOV) PET/CT scanners as transformative for whole-body perfusion imaging and systemic disease evaluation across cancer, cardiovascular, and neurodegenerative conditions. - ImmunoPET with LAFOV scanners unlocks unprecedented opportunities for personalized cancer therapies by targeting both tumor antigens and immune cells, according to Dr. Erik Aarntzen of University Medical Center Groningen. - PET/MRI is emerging as the platform of choice for neuromolecular imaging, enabling simultaneous acquisition of molecular and multiparametric structural data with significantly reduced radiation exposure. - Global access to theranostics is expanding through innovative financing models, strategic partnerships, and flexible delivery pathways, with programs demonstrating success in both industrialized and resource-limited settings.
- The RECOVER trial enrolled 493 patients with severe treatment-resistant depression who had failed an average of 13 prior treatments and lived with depression for a mean of 29 years. - At 12 months, 69% of patients receiving active VNS showed meaningful improvement, and over 80% of responders maintained or improved their benefits at 24 months. - Among patients with the strongest 12-month response (≥50% symptom reduction), 92% were still showing benefit at two years, with one in five patients effectively free of depressive symptoms. - Roughly one-third of patients who showed no meaningful benefit at 12 months went on to improve by 24 months, suggesting VNS may have a delayed onset in some individuals.
- Washington University in St. Louis received a $1.47 million NIA R01 renewal to evaluate suvorexant's chronic effects on Alzheimer's biomarkers in a six-month, 200-participant randomized trial. - Prior research showed suvorexant acutely reduced the CSF phosphorylated tau-181 to unphosphorylated tau-181 ratio, a key fluid biomarker of tau pathology. - The trial targets cognitively normal, amyloid-positive adults aged 65+ with insomnia, positioning suvorexant as a candidate for secondary prevention rather than symptom management. - Suvorexant, a dual orexin receptor antagonist, offers a distinct mechanistic approach from anti-amyloid immunotherapies by potentially reducing ongoing production of pathological proteins through sleep improvement.
- A JAMA Internal Medicine study of over one million U.S. veterans found Covid vaccination was associated with a nearly 24% reduction in all-cause cardiac events, including heart attacks and strokes. - The protective effect was greatest among adults aged 75 and older and those with chronic kidney or lung disease, potentially preventing 3,500 major cardiac events and 2,400 deaths per million people annually. - Researchers propose that vaccines prevent silent or undiagnosed SARS-CoV-2 infections from triggering endothelial inflammation and clotting cascades that lead to cardiac events. - A separate CDC-led study in the same journal issue found 2024-2025 Covid vaccines were 41% effective against critical illness in adults 18 and older.
- A first-in-class PET radiotracer, 18F-OXD-2314, demonstrated elevated uptake in grey-white matter junctions of retired athletes with suspected CTE compared to healthy controls. - The tracer also showed binding in all post-mortem CTE tissue examined, providing early biological confirmation of its ability to detect tau pathology specific to CTE. - Separately, the Alzheimer's-associated protein eMTBR-tau243 showed stage-specific increases in blood samples from donors with confirmed CTE pathology, rising from Stage I to Stage IV disease. - Both approaches could provide the first accurate in-life diagnostic biomarkers for CTE, potentially enabling clinical trials and offering patients clarity within the next two years.
- A landmark clinical trial involving 1,658 participants across six U.S. academic centers found that a structured behavioral hydration program using smart bottles and coaching failed to significantly reduce kidney stone recurrence rates. - Despite participants modestly increasing their urine output through the intervention, the improvement was insufficient to prevent symptomatic stone recurrence compared to standard care over the two-year study period. - The findings highlight the significant challenge patients face in maintaining the high fluid intake necessary for kidney stone prevention, even with technological support and financial incentives. - Researchers suggest the need for more personalized approaches to kidney stone prevention, as a single hydration target may not work for all patients due to varying individual factors.
- Circular Genomics completed exclusive intellectual property licensing agreements with Washington University in St. Louis and the Max Delbrück Center for foundational circRNA biomarker technology in Alzheimer's disease. - The licenses provide exclusive commercial rights covering identification, measurement, and clinical application of circRNA biomarkers across the entire Alzheimer's disease continuum from preclinical to symptomatic stages. - The company is developing a minimally invasive, blood-based circRNA test designed to enable earlier detection and improved disease characterization for Alzheimer's patients. - Circular RNAs represent a biologically distinct class of RNA molecules that are enriched in brain tissue, resistant to degradation in blood, and increasingly implicated in neurodegenerative disease biology.
- The University of Cincinnati is leading a multicenter clinical trial to test extended oral tranexamic acid (TXA) dosing for seven days after ACL reconstruction surgery to improve recovery outcomes. - The randomized controlled trial will enroll 100 participants aged 14-22 across six medical centers, comparing extended TXA treatment to placebo for post-surgical recovery. - Extended TXA dosing has shown improved results in joint replacement procedures and may reduce pain, swelling, and promote earlier movement in ACL patients. - Researchers expect the treatment could prevent arthrogenic muscle inhibition and allow athletes to return to sports sooner than the typical 9-12 month recovery period.
- BostonGene published a study in Cell Reports Medicine introducing the largest harmonized transcriptomic and clinical dataset in kidney cancer, analyzing over 3,600 patient samples. - Researchers developed a multimodal AI foundation model that identified five novel Harmonized Immune Tumor Microenvironment (HiTME) subtypes in clear cell renal cell carcinoma. - The AI model generated clinically interpretable responder scores that correlated with survival outcomes for both immune checkpoint inhibitors and VEGF inhibitors across independent cohorts. - The framework revealed a therapy-resistant subgroup characterized by immune-desert phenotypes and angiogenic signaling, highlighting new therapeutic opportunities.
- FDA approves Ocugen's investigational new drug application for a nasal COVID-19 vaccine, developed at Washington University in St. Louis, advancing to Phase 1 clinical trials this spring. - The innovative vaccine, designed to induce immunity in the upper respiratory tract, will be evaluated in 80 adults through both nasal spray and inhalation routes under NIAID sponsorship. - Early animal studies demonstrated the vaccine's potential to prevent infection and viral transmission, offering advantages over traditional injectable COVID-19 vaccines.
